Diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF), is a complex cardiovascular condition characterized by the heart’s inability to relax and fill properly during diastole. Unlike systolic heart failure, where the heart struggles to pump blood effectively, diastolic heart failure occurs when the left ventricle becomes stiff or less compliant, leading to increased filling pressures and subsequent congestion. Understanding the pathophysiology of diastolic heart failure is crucial for clinicians, medical students, and patients to recognize the mechanisms, risk factors, and consequences of this condition, ultimately guiding effective diagnosis and management.
Overview of Diastolic Heart Failure
Diastolic heart failure is a form of heart failure in which the left ventricle maintains near-normal systolic function but demonstrates impaired relaxation and filling. This condition primarily affects the elderly and is more common in women, often associated with comorbidities such as hypertension, diabetes mellitus, obesity, and coronary artery disease. The hallmark of diastolic dysfunction is elevated left ventricular end-diastolic pressure despite a preserved ejection fraction.
Key Mechanisms
The pathophysiology of diastolic heart failure involves multiple mechanisms that contribute to impaired ventricular relaxation, increased stiffness, and abnormal filling patterns. These include structural, cellular, and neurohormonal changes
Structural Changes in the Heart
Structural alterations in the myocardium play a central role in diastolic dysfunction. Common changes include
- Left ventricular hypertrophy – often due to chronic hypertension, which increases afterload and stimulates myocardial thickening.
- Myocardial fibrosis – accumulation of collagen and extracellular matrix proteins increases ventricular stiffness and reduces compliance.
- Aging-related changes – age-related myocardial stiffening contributes to decreased ventricular elasticity and impaired filling.
Cellular and Molecular Alterations
At the cellular level, several processes contribute to impaired diastolic function
- Impaired calcium handling – abnormal calcium reuptake during diastole delays relaxation of cardiac myocytes.
- Myocyte hypertrophy – enlarged cardiomyocytes reduce the ventricular chamber compliance.
- Altered titin protein function – titin, a structural protein in sarcomeres, affects myocardial elasticity and contributes to stiffness when its properties are altered.
Hemodynamic Consequences
Diastolic dysfunction leads to distinct hemodynamic changes, including
- Elevated left ventricular end-diastolic pressure – due to reduced compliance, resulting in increased filling pressures.
- Left atrial enlargement – chronic pressure overload causes atrial dilation and potential atrial fibrillation.
- Pulmonary congestion – increased left-sided pressures are transmitted backward into the pulmonary circulation, causing dyspnea and exercise intolerance.
Neurohormonal Activation
Neurohormonal systems play a role in the progression of diastolic heart failure
- Renin-angiotensin-aldosterone system (RAAS) – activation promotes sodium and water retention, worsening congestion and ventricular remodeling.
- Sympathetic nervous system – increased adrenergic tone raises heart rate and vascular resistance, further impairing relaxation.
- Inflammatory mediators – cytokines such as TNF-alpha and interleukins contribute to myocardial fibrosis and stiffness.
Clinical Manifestations
The pathophysiological changes of diastolic heart failure translate into characteristic clinical symptoms and signs. These include
- Dyspnea – especially on exertion or when lying down (orthopnea), due to pulmonary congestion.
- Fatigue – reduced cardiac output impairs oxygen delivery to tissues.
- Peripheral edema – fluid retention in the lower extremities, though less prominent than in systolic heart failure.
- Exercise intolerance – elevated filling pressures limit cardiac reserve.
Diagnostic Indicators
Several diagnostic tools assess the pathophysiological features of diastolic heart failure
- Echocardiography – evaluates left ventricular wall thickness, diastolic filling patterns, and left atrial size.
- BNP and NT-proBNP levels – biomarkers that increase in response to elevated filling pressures.
- Cardiac MRI – provides detailed imaging of myocardial structure and fibrosis.
- Hemodynamic measurements – invasive catheterization can assess left ventricular end-diastolic pressures directly.
Risk Factors and Contributing Conditions
Several conditions increase the risk of developing diastolic heart failure
- Chronic hypertension – a major contributor to left ventricular hypertrophy and increased stiffness.
- Diabetes mellitus – promotes microvascular dysfunction and myocardial fibrosis.
- Obesity – increases cardiac workload and systemic inflammation.
- Ischemic heart disease – myocardial ischemia and infarction can impair relaxation.
- Aging – structural and cellular changes in the heart reduce compliance over time.
Therapeutic Considerations
Management of diastolic heart failure focuses on addressing the underlying pathophysiology and relieving symptoms
- Blood pressure control – reduces afterload and left ventricular hypertrophy.
- Diuretics – relieve pulmonary congestion and peripheral edema.
- Heart rate control – slower heart rates improve diastolic filling.
- Management of comorbidities – diabetes, obesity, and ischemic heart disease require targeted therapy.
- Exercise and lifestyle interventions – improve functional capacity and reduce cardiac stress.
The pathophysiology of diastolic heart failure involves complex interactions between structural, cellular, and neurohormonal factors that impair ventricular relaxation and increase filling pressures. Left ventricular hypertrophy, myocardial fibrosis, impaired calcium handling, and neurohormonal activation contribute to elevated pressures, pulmonary congestion, and clinical symptoms such as dyspnea and fatigue. Understanding these mechanisms is essential for early recognition, accurate diagnosis, and effective management of HFpEF. Targeted interventions, including blood pressure control, diuretics, and lifestyle modifications, aim to reduce symptoms, prevent disease progression, and improve quality of life for patients living with diastolic heart failure.